Search company, investor...

ADC Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About ADC Therapeutics

ADC Therapeutics (ADCT) is an oncology drug development company that specializes in the development of Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The company's ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca's MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

Headquarters Location

Route de la Corniche 3B

Epalinges, CH-1066,


+41 21 653 02 00

Missing: ADC Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ADC Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ADC Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ADC Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ADC Therapeutics Patents

ADC Therapeutics has filed 259 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Experimental cancer drugs
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Experimental cancer drugs, Indoles, Clusters of differentiation, Immunology


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Experimental cancer drugs, Indoles, Clusters of differentiation, Immunology



Latest ADC Therapeutics News

Camidanlumab tesirine by ADC Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Jun 5, 2023

Brought to you by Camidanlumab tesirine is under clinical development by ADC Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Camidanlumab tesirine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Camidanlumab tesirine overview Camidanlumab tesirine is under development for the treatment of CD25-expressing relapsed/refractory Hodgkin lymphoma, relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms, Non-Hodgkin lymphoma. The therapeutic candidate is administered as an intravenous infusion. ADCT-301 is an antibody drug conjugate composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug–antibody ratio of 2.3. It was also under development for prostate cancer, relapsed or refractory CD25-positive acute lymphocytic leukemia (ALL). It was under devlopment for the treatment of advanced solid tumors including head and neck squamous cell carcinoma, fallopian tube cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, pancreas cancer, bladder cancer, renal cell carcinoma, melanoma, triple-negative breast cancer, ovarian cancer and colorectal cancer ADC Therapeutics overview ADC Therapeutics is a biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It offers Zynlonta, a CD-19-directed antibody for treatment of e B-cell lymphoma in adult patients. The company is provides Loncastuximab Tesirine (Lonca)and Camidanlumab Tesirine (Cami). ADC Therapeutics develops ADCT-602 drug for B-cell acute lymphoblastic leukemia, ADCT-601 targeting AXL in solid tumors, ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer and myeloid leukemia. The company has operations in London, the UK and New Providence, and San Mateo, the US. ADC Therapeutics is headquartered in Lausanne, Switzerland. For a complete picture of Camidanlumab tesirine’s drug-specific PTSR and LoA scores, buy the report here. Subscribe to our Newsletter

ADC Therapeutics Frequently Asked Questions (FAQ)

  • When was ADC Therapeutics founded?

    ADC Therapeutics was founded in 2011.

  • Where is ADC Therapeutics's headquarters?

    ADC Therapeutics's headquarters is located at Route de la Corniche 3B, Epalinges.

  • What is ADC Therapeutics's latest funding round?

    ADC Therapeutics's latest funding round is IPO.

  • How much did ADC Therapeutics raise?

    ADC Therapeutics raised a total of $693M.

  • Who are the investors of ADC Therapeutics?

    Investors of ADC Therapeutics include Deerfield Management, Auven Therapeutics, AstraZeneca, Redmile Group, Wild Family Office and 4 more.

  • Who are ADC Therapeutics's competitors?

    Competitors of ADC Therapeutics include Evive Biotech.

Compare ADC Therapeutics to Competitors

Evive Biotech

Evive Biotech is an integrated biotech company developing therapeutic biologics. Products under development are mainly aimed at unsolved medical problems, such as oncology, inflammation, and autoimmune diseases. The company was formerly known as Generon Biomed, Inc. and changed its name to Evive Biotech in June 2020. The company was founded in 2004 and is based in Singapore, Singapore.

Bluebird Bio Logo
Bluebird Bio

Bluebird Bio is developing gene therapies for severe genetic disorders. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of treatments for diseases with few or no clinical options. The company's approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio's approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy.

Achilles Therapeutics Logo
Achilles Therapeutics

Achilles Therapeutics (NASDAQ: ACHL) is a biopharmaceutical company. It develops personalized T cell therapies targeting neoantigens protein markers that are present on the surface of a cancer cell and can be detected by the immune system. It was founded in 2016 and is based in London, United Kingdom.

Audentes Therapeutics Logo
Audentes Therapeutics

Audentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Juno Therapeutics

Juno Therapeutics is a clinical-stage company that brings together three cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children's Research Institute – in a partnership to advance a broad pipeline of immunotherapies. Juno will build on the foundation of immunotherapies to develop two distinct and complementary platforms – CARs and TCRs. The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. The company's goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

Kite Pharma Logo
Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing immunotherapies and other oncology treatments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.